Publication date: May 12, 2019
To assess the efficacy of intravitreal aflibercept in patients suffering from post-radiation macular edema following plaque radiotherapy for choroidal melanoma.
This prospective, interventional case series included patients affected by radiation maculopathy (RM) with macular edema secondary to ruthenium-106 plaque brachytherapy for choroidal melanoma. The effect of intravitreal aflibercept on best-corrected visual acuity (BCVA), central foveal thickness (CFT) detected by spectral domain optical coherence tomography (sd-OCT), and Horgan’s grading scale of RM was evaluated throughout the 24-month follow-up. Intraocular pressure (IOP) and possible complications were also recorded.
Nine eyes of 9 patients were included. A mean of 4.4 +/- 1.2 injections were given over the 24 months. At the end of follow-up, mean BCVA was significantly improved, from 0.9 +/- 0.19 logMAR at baseline to 0.56 +/- 0.3 logMAR (P = 0.028), and mean CFT was significantly decreased, from 546 +/- 123 μm at baseline to 223 +/- 34 μm (P
Fallico, M., Reibaldi, M., Avitabile, T., Longo, A., , Bonfiglio, Chronopoulos, A., Caltabiano, R., Spatola, C., and Russo, A. Intravitreal aflibercept for the treatment of radiation-induced macular edema after ruthenium 106 plaque radiotherapy for choroidal melanoma. 22600. 2019 Graefes Arch Clin Exp Ophthalmol.
- Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.